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Introduction
Lung cancer, as a leading cause of cancer-related mortality, is responsible for approximately 1.4 million deaths annually throughout the world (1) . The major etiological agent for lung cancer is tobacco smoke and air pollution (2) (3) (4) (5) (6) . Although more than 60 carcinogenic compounds have been identified so far in each single cigarette, B[a]P and its metabolite B[a]PDE are the most important and the strongest complete lung carcinogens (7) . The carcinogenic capacity of B[a]P is supported by epidemiological studies and has been proven in studies both in vitro and in vivo (8, 9) . The sustained existence of chronic lung inflammation is a major driving force for the development of lung cancers (10) . Although the link between chronic airway inflammation and lung carcinogenesis is well established, the molecular mechanisms responsible for the generation of steady increases in chronic lung inflammation have not been investigated.
Growing evidence indicates that a chronic inflammatory microenvironment in the lung is a major driving force for the development of lung cancer (11) . PAHs and their derivatives, such as B[a]P/B[a]PDE, are strong carcinogens that actively promote inflammation and cancers of the lung (12, 13) . Our previous studies demonstrate that TNFα is an essential inflammatory mediator for cell neoplastic transformation upon B[a]PDE exposure (14) . Although our published studies reveal that transactivation of transcription factor NFAT plays an important role in mediating TNFα induction upon B[a]PDE exposure, NFAT transactivation is not consistent with the sustained TNFα transcriptional induction (14) . Thus, current studies aim to explore the molecular mechanisms underlying the sustained activities, and can inhibit AKT (15，16), PKC (17) and p70S6 Kinase phosphorylation and activation by specifically dephosphorylating these kinases at their key regulatory domains (18) . Since these PHLPP substrates positively regulate growth factor-induced signalling, PHLPP exhibits its specific characterization as a suppressor of cancer cell proliferation (19) . Although PHLPP2 expression has been reported to be downregulated in cancer tissues (20) (21) (22) , its potential contribution to environmental carcinogenesis has not yet been studied. Moreover, association of PHLPP2 with lung inflammation and tumorigenesis has never been explored to the best of our knowledge. Thus, our studies address these important questions in both in vitro cell culture model and in vivo animal model. The majority of the important findings were also extended to in vivo human studies.
Materials and Methods

Chemical Reagents and Plasmids
Benzo[a]pyrene (B[a]P) was purchased from Sigma Aldrich (Milwaukee, WI, USA).
Benzo [alpha] pyrene-7,8-diol-9,10-epoxide (B[a]PDE) was a generous gift from Dr. Shantu Amin, Department of Pharmacology, School of Medicine, the Pennsylvania State University (Hershey, PA) as described in our previous studies (23) . Protein synthesis inhibitor cyclohexamide (CHX) was bought from Calbiochem (San Diego, CA, USA). The dual luciferase assay kit was purchased from Promega (Milwaukee, WI, USA). HA-PHLPP2 expression construct was obtained from Addgene (16) . The PHLPP2-3'-UTR luciferase reporter has been cloned into pGL3 vector to detect the 3'-UTR activity as described in our previous study (24) . TNFα promoter-driven luciferase reporter was described in our previous study (14) . miR-494 and its control vector were a kindly gift from Dr. K. Yoshida (Meiji University, Kawasaki, Kanagawa, Japan) (25) . miR-205 expression construct was obtained from Addgene (26) .
Cell culture and Transfection
Beas-2B and A549 cell lines were used for in vitro experiment (Cell lines were originally obtained from ATCC; both cell lines are regularly authenticated on the basis of viability, recovery, growth, morphology and chemical response as well, most recently confirmed 3-4 months before use). Cells were cultured as previously described (27) . Cell transfections were performed by using PolyJet TM 
DNA In
Vitro Transfection Reagent, according to the manufacturer's instruction.
RT-PCR
Cells were treated with B[a]PDE for the indicated time points, and then 5.0 μg total RNA was used for first-strand cDNA synthesis with oligodT (20) primer by SuperScript TM First-Strand Synthesis system (Invitrogen). The phlpp2 and tnfα were determined by PCR. The results were imaged with Α Innotech SP image system (Α Innotech Corporation).
Western Blot
The antibodies specific against p-c-Jun(Ser63), p-c-Jun(Ser73), c-Jun, p-CREB(Ser133), CREB, p-Elk(Ser383), PTEN, p-AKT (Ser473), TNFα and PARP were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies specific to PHLPP1 and PHLPP2 were bought from Bethyl Laboratories, Inc. (Montgomery, TX, USA). HA antibody was purchased from Covance Inc.
(Princeton, NJ, USA). Antibodies against NFAT3, Sp-1 and GAPDH were bought from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against β-Actin or α-Tubulin were purchased from Sigma (St. Louis, MO, USA). Western blotting was performed as described in our previous publication (27) .
[
35
S]methionine pulse assay
The pulse assay was performed as described in our previous publication (28) .
Animal experiments and lung tissue
The C57BL / 6J female mice at age of 6∼8 weeks were randomly divided into 4 groups as indicated in Supplementary Table 2 . B[a]P exposure groups (tnfα+/+; tnfα-/-), each of mice was exposed to B[a]P (1mg/mouse, dissolved in 50 μl tricaprylin solvent) by intratracheal instillation. The intratracheal instillation was repeated weekly for 4 weeks and control groups (tnfα+/+; tnfα-/-) received the same amount of tricaprylin solvent only. The mice from the B[a]P and tricaprylin control groups were then sacrificed at different periods after last exposure to evaluate the expression of PHLPP2 and TNFα and/or lung pathological analysis.
Immunohistochemistry Paraffin (IHC-P) of Human and Mouse Lung Specimens.
Lung tissues obtained from the sacrificed mice or human lung cancer specimens were formalin-fixed and paraffin-embedded. For immunohistochemical staining (IHC), we used antibodies specific against PHLPP2 (LifeSpan BioSciences, Seattle, WA) or TNFα (Abcam, Cambridge, MA). The resultant immunostaining images were captured using the AxioVision Rel.4.6 computerized image analysis system (Carl Zeiss, Oberkochen, Germany). Protein expression levels were analyzed by calculating the integrated optical density per stained area (IOD/area) using Image-Pro Plus version 6.0 (Media Cybernetics, MD, USA).More detailed procedure was described as supplementary information.
Luciferase Reporter Assay
Luciferase activity determination was performed as described in our studies previously (29) .
Research. 
Cell transformation
Cell transformation was performed as described in our studies previously (27) . Cells were exposed to 1 μM B[a]PDE for 12-24 h and then B[a]PDE-containing medium was removed and B[a]PDE-treated cells were re-cultured in fresh 10% FBS DMEM for 2 days. The cultures were split and subjected to another round of treatment. Such B[a]PDE exposure was repeated twice a week for 3-4 months. For the TNFα-induced cell transformation, the cells were treated with 10% FBS DMEM containing 5U/ml TNFα for 2 days and such treatment was applied to cells twice per week for total 3∼4 months, then the anchorage-independent growth capability of the treated cells was subjected to soft agar assay (14, 30) .
Soft agar assay
Anchorage-independent growth ability of B[a]PDE-or TNFα-treated cells was evaluated in soft agar as described in our previous study (31) .
Statistical Methods
Statistical analysis was performed by Prism 5.0 Software (Graph-pad software, San Diego, CA).
ANOVA was employed to determine the significance of differences between various groups. The differences will be considered significant at p＜0.05. body weight has been used successfully in many in vivo mouse studies (33, 34 Figures 1A and 1B 
Results
Downregulation
PHLPP2 downregulation by B[a]PDE mediated Beas-2B cell transformation
To determine the potential contribution of PHLPP2 downregulation to the lung tumorigenic effect of For the past decade, miRNA has been a well-documented and pivotal factor for regulating physiological and pathological processes through its ability to regulate mRNA stability and protein translation (37, 38) . To further uncover the mechanism of B[a]PDE in the modulation of PHLPP2 translation, the PHLPP2-3'UTR-dependent luciferase reporter was stably transfected into Beas-2B cells and the effect of B[a]PDE exposure on PHLPP2-3'UTR-dependent luciferase activity was determined.
As shown in Figure 3E 
PHLPP2 downregulation contributes to inflammatory TNFα induction by B[a]PDE
The sustained existence of chronic lung inflammation is a major driving force for the development of lung cancers (11, 39) . TNFα plays an important role in promoting tumor growth and progression by regulating chronic inflammation (40 We found that, chronic lung inflammation and the formation of atypical hyperplasia and carcinoma upon B[a]P exposure observed in wild-type mice were almost impaired in TNFα knockout mice, although PHLPP2 expression was still downregulated in TNFα KO mouse lung tissues ( Figures S5B and S5C ).
In summary, our current study for the first time discovers a PHLPP2 downregulation by 
